CALC trial: Aprepitant for the treatment of cough in lung cancer

ISRCTN ISRCTN16200035
DOI https://doi.org/10.1186/ISRCTN16200035
Secondary identifying numbers 13989
Submission date
26/03/2013
Registration date
26/03/2013
Last edited
24/09/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-at-aprepitant-to-treat-cough-in-people-with-lung-cancer-calc

Contact information

Dr Amelie Harle
Scientific

Department of Medical Oncology
550 Wilmslow Road
Manchester
M20 4BX
United Kingdom

Email Amelie.Harle@christie.nhs.uk

Study information

Study designRandomised single-arm placebo-controlled crossover study
Primary study designInterventional
Secondary study designRandomised cross over trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleA single-arm double-blind placebo-controlled cross-over trial of Aprepitant for the treatment of cough in lung cancer: CALC trial
Study acronymCALC
Study objectivesA single-arm placebo controlled crossover study of Aprepitant for the treatment of cough in lung cancer.

Aprepitant is an effective antitussive for patients with lung cancer.
Ethics approval(s)NRES Committee North West – Liverpool East, 22/03/2013, ref: 13/NW/0084
Health condition(s) or problem(s) studiedTopic: National Cancer Research Network; Subtopic: Lung Cancer; Disease: Lung (small cell), Lung (non-small cell)
InterventionPatients will receive 3 days treatment with aprepitant/placebo at standard doses: 125mg D1, 80mg D2 and 80mg D3 followed by 3 days washout period and 3 further days of aprepitant/placebo at standard doses.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Aprepitant
Primary outcome measureDaytime ambulatory cough monitoring; Timepoint(s): Baseline, D3 and D9
Secondary outcome measures1. Biomarker Analysis; Timepoint(s): Day 3 and Day 9
2. Cough Severity Visual Analogue Scale score; Timepoint(s): Baseline, Day 3 and Day 9
3. Manchester Cough in Lung Cancer Scale score; Timepoint(s): Baseline, Day 3 and Day 9
Overall study start date01/04/2013
Completion date31/03/2014

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 20; UK Sample Size: 20
Total final enrolment20
Key inclusion criteria1. Patients willing and able to give consent for participation in the trial
2. Male or female aged 18 years or above
3. WHO PS 02
4. Diagnosed with lung cancer
5. Able and willing to participate in and comply with the trial schedule
6. Persistent cough >= 4 weeks
7. Not on anticancer therapy
8. No anticancer therapy planned to commence for the duration of the trial participation
Key exclusion criteria1. Received anticancer therapy within 4 weeks of trial entry
2. Receiving Aprepitant therapy
3. Presence of a RTI within last 4 weeks
4. Previous adverse event to Aprepitant
5. Presence of constipation grade 2 or above (CTCAE v4)
6. Scheduled elective surgery or other procedures requiring sedation or general anaesthesia during trial period
7. Potentially fertile women of childbearing age
8. Currently participating in another research trial involving an investigational product
9. Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial or affect the patient’s ability to participate in the trial
Date of first enrolment01/04/2013
Date of final enrolment31/03/2014

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Christie Hospital NHS Foundation Trust
Manchester
M20 4BX
United Kingdom

Sponsor information

Christie Hospital NHS Foundation Trust (UK)
Hospital/treatment centre

550 Wilmslow Road
Manchester
M20 4BX
England
United Kingdom

Website http://www.christie.nhs.uk/
ROR logo "ROR" https://ror.org/03v9efr22

Funders

Funder type

Government

National Institute for Health Research (NIHR) (UK)
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom
North West Lung Centre Charity (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Plain English results No Yes
Results article results 10/10/2015 Yes No
Results article results 15/03/2021 24/09/2020 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

24/09/2020: The following changes have been made:
1. Publication reference added.
2. The total final enrolment number has been added from the reference.
19/03/2019: Link to results (plain English) added.
07/02/2017: Publication reference added.